Investigation of mechanisms of neuro-protective effect of semax in acute period of ischemic stroke

This pioneering study by Miasoedova, Skvortsova, Nasonov, and colleagues was among the first to investigate the specific mechanisms behind Semax's neuroprotective effects during acute ischemic stroke, laying the groundwork for its clinical adoption.

The researchers studied patients and animal models during the acute phase of ischemic stroke, examining how Semax at doses of 100-150 micrograms per kilogram affected vascular protection, oxygen deprivation resistance, and inflammatory markers. They measured cytokine levels in cerebrospinal fluid to understand the immunological mechanisms at play.

The findings demonstrated that Semax provided significant angioprotective (blood vessel protective) and antihypoxic (oxygen deprivation resistance) effects during acute stroke. The key mechanistic discovery was that Semax shifted the inflammatory balance — promoting anti-inflammatory cytokines like interleukin-10 while suppressing pro-inflammatory markers including interleukin-8 and C-reactive protein. This immune rebalancing appeared central to its neuroprotective effects.

This foundational study was instrumental in establishing Semax as a clinically approved treatment for stroke recovery in Russia. By demonstrating both the clinical benefit and the specific immunological mechanism, it provided the evidence base that has supported decades of clinical use. The cytokine-balancing mechanism discovered here remains one of the best-understood pathways of peptide-mediated neuroprotection.